SCHEMBL255039

SCHEMBL255039

CC(C)NCCc1ccc(N)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.52
MAOB P27338 4/20 0.45
MAOA P21397 2/20 0.45
SIGMAR1 Q99720 3/20 0.44
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ADRB2 P07550 2/20 0.42
LMNA P02545 2/20 0.42
HIF1A Q16665 2/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
OPRM1 P35372 2/20 0.42
OPRK1 P41145 2/20 0.42
CYP2D6 P10635 1/20 0.42
GALR3 O60755 1/20 0.42
ADRB1 P08588 1/20 0.42
ADRA1A P35348 1/20 0.42
SLC6A3 Q01959 1/20 0.42
ESRRG P62508 1/20 0.41
ADRB3 P13945 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15031576 0.83 LMNA (0.50) SIGMAR1HTTSMN1; SMN2ADRB2LMNA
SCHEMBL23695828 0.81 SIGMAR1 (0.49) SIGMAR1HTTSMN1; SMN2ADRB2LMNA
SCHEMBL13996937 0.81 L3MBTL1 (0.47) SIGMAR1HTTSMN1; SMN2ADRB2LMNA
SCHEMBL10087662 0.81 ALDH1A1 (0.47) SIGMAR1HTTSMN1; SMN2ADRB2LMNA
SCHEMBL24419730 0.80 ESR1 (0.45) SIGMAR1HTTSMN1; SMN2ADRB2LMNA
SCHEMBL9911348 0.79 LMNA (0.64) SIGMAR1HTTADRB2LMNAHIF1A
SCHEMBL20024425 0.79 SIGMAR1 (0.53) SIGMAR1HTTSMN1; SMN2ADRB2LMNA
SCHEMBL13532079 0.79 TAAR1 (0.61) SIGMAR1HTTSMN1; SMN2ADRB2LMNA
SCHEMBL254706 0.79 TAAR1 (0.61) SIGMAR1HTTSMN1; SMN2ADRB2LMNA
SCHEMBL3084431 0.79 TAAR1 (0.61) SIGMAR1HTTSMN1; SMN2ADRB2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116940562-A Acetamido-phenylbenzamide derivatives and methods of use thereof 希华医药有限公司 2023-10-24 CN disclosed
EP-4225745-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME Athenex, Inc. (US) 2023-08-16 EP disclosed
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ NATIONAL INSTITUTES OF HEALTH 2023-05-11 US disclosed
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ NATIONAL INSTITUTES OF HEALTH 2023-05-11 US disclosed
WO-2022076662-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME ATHENEX, INC. (US) 2022-04-14 WO disclosed
US-20220106301-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME Health Hope Pharma Limited (HK) 2022-04-07 US disclosed
US-9918473-B2 Use of aryl carbamates in agriculture and other plant-related areas North Carolian State University (US) 2018-03-20 US disclosed
EP-3002287-A1 Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors National Defense Medical Center (TW) 2016-04-06 EP disclosed
WO-2015120730-A1 THIOCHROMENO[2,3-C]QUINOLIN-12-ONE DERIVATIVES, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 黄旭山 2015-08-20 WO disclosed
US-8927717-B1 Thiochromeno[2,3-c]quinolin-12-one derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2015-01-06 US disclosed
US-8906376-B2 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease SEATTLE GENETICS, INC. (US) 2014-12-09 US disclosed
WO-2012030986-A2 USE OF ARYL CARBAMATES IN AGRICULTURE AND OTHER PLANT-RELATED AREAS NORTH CAROLINA STATE UNIVERSITY (US) 2012-03-08 WO disclosed
US-20110064753-A1 DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE SEATTLE GENETICS, INC. (US) 2011-03-17 US disclosed
US-7851437-B2 monoclonal antibody conjugated with peptide drug such as dolastatin derivative SEATTLE GENETICS INC. (US) 2010-12-14 US disclosed
US-7829531-B2 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease SEATTLE GENETICS INC. (US) 2010-11-09 US disclosed
US-20100062008-A1 monoclonal antibody conjugated with peptide drug such as dolastatin derivative SEATTLE GENETICS, INC. (US) 2010-03-11 US disclosed
US-7659241-B2 monoclonal antibody conjugated with peptide drug such as dolastatin derivative SEATTLE GENETICS, INC. (US) 2010-02-09 US disclosed
US-20090324621-A1 monoclonal antibody conjugated with peptide drug such as dolastatin derivative SEATTLE GENETICS, INC. (US) 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110064753-A1 DRUG CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE CD47, CD2, CD22 GFER 1679/4885MAOB 3077/4885MAOA 2962/4885
US-20100062008-A1 monoclonal antibody conjugated with peptide drug such as dolastatin derivative DAD1, DDOST, STT3A GFER 3657/4885MAOB 4285/4885MAOA 4482/4885
US-20220106301-A1 ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME ABCB1, ABCC1, UGT2B7 GFER 1175/4885MAOB 87/4885MAOA 285/4885
US-20090324621-A1 monoclonal antibody conjugated with peptide drug such as dolastatin derivative DAD1, DDOST, STT3A GFER 3657/4885MAOB 4285/4885MAOA 4482/4885
US-20230143470-A1 SMALL MOLECULE INHIBITORS OF INFLUENZA HEMAGGLUTININ HAVCR2, CD44, ENGASE GFER 3542/4885MAOB 688/4885MAOA 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.